We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

37 hedge funds and large institutions have $20.2M invested in Gyre Therapeutics in 2024 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,781% more call options, than puts

Call options by funds: $1.1M | Put options by funds: $16K

175% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 4

150% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 6

35% more capital invested

Capital invested by funds: $15M → $20.2M (+$5.19M)

23% more funds holding

Funds holding: 30 → 37 (+7)

0.25% more ownership

Funds ownership: 1.47% → 1.72% (+0.25%)

Holders
37
Holders Change
+7
Holders Change %
+23.33%
% of All Funds
0.53%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
15
Reduced
6
Closed
4
Calls
$1.1M
Puts
$16K
Net Calls
+$1.08M
Net Calls Change
+$59K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.4M
2
Charles Schwab
Charles Schwab
California
+$1.17M
3
Northern Trust
Northern Trust
Illinois
+$800K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$565K
5
AACP
Advantage Alpha Capital Partners
California
+$343K

Top Sellers

1
WG
Winton Group
United Kingdom
-$220K
2
Renaissance Technologies
Renaissance Technologies
New York
-$166K
3
Marshall Wace
Marshall Wace
United Kingdom
-$128K
4
New York State Common Retirement Fund
New York State Common Retirement Fund
New York
-$96.7K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$74.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$6.45M +$193K +14,932 +3%
Vanguard Group
2
Vanguard Group
Pennsylvania
$4.27M +$1.4M +108,530 +47%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$3.81M +$565K +43,840 +17%
Charles Schwab
4
Charles Schwab
California
$1.43M +$1.17M +90,557 +392%
State Street
5
State Street
Massachusetts
$1.31M +$108K +8,412 +9%
Northern Trust
6
Northern Trust
Illinois
$1.19M +$800K +62,058 +190%
AACP
7
Advantage Alpha Capital Partners
California
$334K +$343K +26,634 New
Goldman Sachs
8
Goldman Sachs
New York
$236K +$242K +18,799 New
Morgan Stanley
9
Morgan Stanley
New York
$229K +$141K +10,949 +151%
Bank of New York Mellon
10
Bank of New York Mellon
New York
$157K -$74.3K -5,759 -32%
RhumbLine Advisers
11
RhumbLine Advisers
Massachusetts
$131K +$1.72K +133 +1%
Barclays
12
Barclays
United Kingdom
$116K +$88.4K +6,855 +282%
Citigroup
13
Citigroup
New York
$63.7K +$45.3K +3,514 +225%
Bank of America
14
Bank of America
North Carolina
$62K -$361 -28 -0.6%
Mirae Asset Global ETFs Holdings
15
Mirae Asset Global ETFs Holdings
Hong Kong
$48.4K +$49.8K +3,861 New
Fidelity Investments
16
Fidelity Investments
Massachusetts
$46.9K +$48.2K +3,742 New
CF
17
Corebridge Financial
Texas
$46.8K -$284 -22 -0.6%
UBS Group
18
UBS Group
Switzerland
$45.7K +$19.6K +1,520 +72%
Wells Fargo
19
Wells Fargo
California
$38.9K +$1.5K +116 +4%
JP Morgan Chase
20
JP Morgan Chase
New York
$38K +$735 +57 +2%
New York State Common Retirement Fund
21
New York State Common Retirement Fund
New York
$33.9K -$96.7K -7,500 -74%
Belvedere Trading
22
Belvedere Trading
Illinois
$31.5K +$32.4K +2,515 New
BNP Paribas Financial Markets
23
BNP Paribas Financial Markets
France
$24.4K +$18.4K +1,427 +274%
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
$12K -$1.14K -88 -8%
TRCT
25
Tower Research Capital (TRC)
New York
$10.8K +$7.85K +609 +245%
1
2

GYRE Hedge Fund Activity: Q3 2024 in Review

37 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2024, worth a combined $20.2M — up 35% from $15M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new GYRE positions and 4 closed out — a net gain of 7 holders — while 15 added to existing stakes and 6 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.4M. The largest seller was Winton Group, exiting entirely with an estimated $220K sold.

  • 37 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2024, up from 30 in Q2 2024.
  • Funds reported $20.2M of Gyre Therapeutics stock for Q3 2024, up 35% quarter-over-quarter.
  • 11 funds opened new Gyre Therapeutics positions in Q3 2024 and 4 closed out, a net change of +7 holders.
  • The largest Gyre Therapeutics buyer in Q3 2024 was Vanguard Group, an estimated $1.4M added.
  • The largest Gyre Therapeutics seller in Q3 2024 was Winton Group, an estimated $220K sold.

Based on aggregated 13F filings for Q3 2024.